News | Sudden Cardiac Arrest | March 12, 2019

Out-of-Hospital Cardiac Arrest Third Leading Cause of Disease-Related Health Loss

Bystander interventions, such as CPR and AED application, significantly reduce death and disability due to out-of-hospital cardiac arrests

Out-of-Hospital Cardiac Arrest Third Leading Cause of Disease-Related Health Loss

March 12, 2019 – Out-of-hospital cardiac arrest was the third leading cause of “health loss due to disease” in the U.S. behind ischemic heart disease and low back/neck pain in 2016, according to new research. The findings were published in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association (AHA) journal.

This study is the first to estimate disability-adjusted life years (DALY) – which measures the sum of years of life lost prematurely and years lived with disability due to a disease – among those who experienced non-traumatic out-of-hospital cardiac arrest in the United States.

Cardiac arrest is an abrupt loss of the heart’s ability to pump, which leads to death within minutes if not treated. Its effect on years lost to premature death and disability is currently unknown.

Using the national Cardiac Arrest Registry to Enhance Survival (CARES) database, researchers examined 59,752 cases of adult, non-traumatic, Emergency Medical Services (EMS)-treated out-of-hospital cardiac arrest from 2016.   

Researchers found:

  • Disability-adjusted life year rates for out-of-hospital cardiac arrest were 1,347 per 100,000 individuals, ranking it as the third leading cause of health loss due to disease in the U.S. behind ischemic heart disease (2,447) and low back and neck pain (1,565);
  • Individuals who experienced out-of-hospital cardiac arrest lost an average of 20.1 healthy years; and
  • At the national level, this resulted in 4.3 million healthy life years lost, representing 4.5 percent of total DALY in the country.

Researchers also measured the effects of bystander intervention – cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) application – on the disease burden of out-of-hospital cardiac arrest. Focusing their analysis on a subpopulation of bystander-witnessed out-of-hospital cardiac arrest events, researchers found that on a national level:

  • Survival to hospital discharge was higher for those who received bystander CPR than for those who did not (21.5 percent vs. 12.9 percent);
  • Bystander CPR alone was associated with 25,317 healthy life years saved; and
  • CPR paired with AED defibrillation was associated with 35,407 healthy life years saved.  

Researchers noted that women tended to have higher DALY values than men, as well as Caucasians compared to African Americans. Additionally, Hispanic race was associated with higher DALY compared with Caucasians.

“Many cardiac arrests occur outside of the hospital, and our results show that bystander interventions reduce death and disability, underscoring the importance of bystander CPR and AED education, as well as national cardiac arrest surveillance,” said Ryan A. Coute, DO, lead study author and emergency medicine resident at the University of Alabama at Birmingham.

Researchers hope that this study may help focus public health policies, resources and future research on resuscitation science.

“Cardiac arrest is unique because survival is dependent on the timely response of bystanders, medical dispatch, EMS personnel, physicians and hospital staff,” Coute said. “We hope that the results of our study provide an opportunity to emphasize the fact that ‘cardiac arrest’ and ‘heart attack’ are not synonymous. Our results may also help inform funding agencies and policy makers regarding how to best utilize limited resources to improve public health.”

For more information: www.ahajournals.org/journal/circoutcomes

Reference

1. Coute R.A., Nathanson B.H., Panchal A.R., et al. Disability-Adjusted Life Years Following Adult Out-of-Hospital Cardiac Arrest in the United States. Circulation: Cardiovascular Quality and Outcomes, March 12, 2019. https://doi.org/10.1161/CIRCOUTCOMES.118.004677

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init